YODA - Trademark Details
Status: 605 - Abandoned - After Publication
Image for trademark with serial number 90106080
Serial Number
90106080
Word Mark
YODA
Status
605 - Abandoned - After Publication
Status Date
2021-08-23
Filing Date
2020-08-11
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s) Typeset
Design Searches
020102, 020137, 021125, 260303 - Shadows or silhouettes of men. Heads, portraits or busts of men in profile. Other parts of the human body. Incomplete ovals.
Published for Opposition Date
2021-07-20
Attorney Name
Hui Zhang
Law Office Assigned Location Code
N70
Employee Name
INGRAM, KYLE G
Statements
Indication of Colors claimed
The color(s) blue, red, white and green is/are claimed as a feature of the mark.
Description of Mark
The mark consists of the stylized wording "YODA" in blue and the design of a side profile of a human head, with the head and neck thereof in white, brain thereof in green and blue, and white cerebral sulcus thereof in white, overlapping the letter "O". An incomplete oval in red is interwoven with the letters "YOD".
Goods and Services
Pharmaceutical preparations for the treatment of central nervous system disorders or diseases, namely, neurological illnesses, psychiatric illnesses, and neurodegenerative diseases; pharmaceutical preparations for the treatment of psychiatric, emotional and behavioral disorders, namely, depression, bi-polar disorder, anxiety, panic disorder, schizophrenia, schizoaffective disorder, positive syndrome, negative syndrome, mood and cognitive related symptoms of psychiatric illnesses, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD); pharmaceutical preparations for the treatment of brain injuries, namely, traumatic brain injury (TBI), brain ischemia, post-stroke recovery, post-hemorrhage recovery, reversible cerebral vasoconstriction syndrome, spinal cord injury, convulsion, epileptic seizures; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD); pharmaceutical preparations for the treatment of loss of memory, cognition, or loss of neuronal functions associated with neurodegenerative diseases or aging; pharmaceutical preparations for the treatment of neurological diseases, namely, ataxia, sporadic or hereditary ataxias, cerebellar ataxia, parkinsonism ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), muscular dystrophy; pharmaceutical preparations for the treatment of neurodevelopmental disorders, namely, Tourette syndrome (TS), autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), developmental language disorder (DLD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of pain, namely, neuropathic pain; Pharmaceutical preparations for the treatment of inflammatory disorder or diseases, namely, inflammasome-related diseases, immunological diseases; pharmaceutical preparations for the treatment of auto-inflammatory diseases or auto-immune diseases, namely, multiple sclerosis (MS), systemic sclerosis (SSc), rheumatoid arthritis (RA), lupus, gout, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, chronic inflammation, auto-inflammatory fever syndromes, cryopyrin-associated periodic syndromes (CAPS); pharmaceutical preparations for the treatment of liver-related inflammatory diseases, namely, chronic liver disease, non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, viral hepatitis; pharmaceutical preparations for the treatment of kidney-related inflammatory diseases, namely, chronic kidney disease (CKD), hypertensive nephropathy, lupus nephritis, Type I diabetes, Type II diabetes, hemodialysis related inflammation; pharmaceutical preparations for the treatment of cardiovascular-related inflammatory diseases, namely, chronic heart disease (CHD), peripheral artery disease (PAD), hypertension, atherosclerosis, acute heart failure, systemic lupus erythematosus (SLE); pharmaceutical preparations for the treatment of neuroinflammation-related diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD), traumatic brain injury (TBI), brain ischemia, ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), multiple sclerosis (MS), muscular dystrophy, Tourette syndrome (TS), autism spectrum disorder (ASD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of age-related inflammatory degenerative diseases, namely, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), parkinsonism-dementia complex of Guam, atherosclerosis, osteoarthritis, neuronal cell death; Pharmaceutical drugs, namely, anti-inflammatory agents, antioxidants, antidepressants, antipsychotics, anti-Parkinson agents, central nervous system agents, stimulants, inhibitors, modulators, benzodiazepines, serotoninergic agents, dopaminergic agents, glutaminergic agents, analgesics, neuromuscular agents, and psychotherapeutic agents
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
005, 006, 018, 044, 046, 051, 052
Class Status Code
8 - Abandoned
Class Status Date
2021-08-23
Primary Code
005
Correspondences
Name
Hui Zhang
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2020-08-14NEW APPLICATION ENTERED IN TRAM
2020-09-11NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2020-09-12NOTICE OF DESIGN SEARCH CODE E-MAILED
2020-12-05ASSIGNED TO EXAMINER
2020-12-07NON-FINAL ACTION WRITTEN
2020-12-07NON-FINAL ACTION E-MAILED
2020-12-07NOTIFICATION OF NON-FINAL ACTION E-MAILED
2021-05-28TEAS RESPONSE TO OFFICE ACTION RECEIVED
2021-05-28CORRESPONDENCE RECEIVED IN LAW OFFICE
2021-05-29TEAS/EMAIL CORRESPONDENCE ENTERED
2021-06-14APPROVED FOR PUB - PRINCIPAL REGISTER
2021-06-30NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2021-07-20PUBLISHED FOR OPPOSITION
2021-07-20OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2021-08-16TEAS EXPRESS ABANDONMENT RECEIVED
2021-08-23ABANDONMENT - AFTER PUBLICATION
2021-08-24ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION